Suppression of murine endotoxin response by E5531, a novel synthetic lipid A antagonist

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 2824-2829

  Kobayashi, Seiichi ^a   Kawata, Tsutomu ^a   Kimura, Akifumi ^a   Miyamoto, Kaname ^a   Katayama, Koichi ^a   Yamatsu, Isao ^a   Rossignol, Daniel P ^b   Christ, William J ^b,c   Kishi, Yoshito ^b  

^a EISAI CO LTD   (Japan)

^b EISAI RESEARCH INSTITUTE   (United States)

^c EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O [2 DEOXY 6 O METHYL 4 O PHOSPHONO 3 O (DODEC 5 ENOYLOXYDECYL) 2 (3 OXOTETRADECANOYLAMIDO) BETA DEXTRO GLUCOPYRANOSYL] 2 DEOXY 3 O 3 HYDROXYDECYL 2 (3 OXOTETRADECANOYLAMIDO) 1 O PHOSPHONO ALPHA DEXTRO GLUCOPYRANOSE TETRASODIUM; BACTERIUM LIPOPOLYSACCHARIDE; E 5531; LIPID A DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; LETHALITY; LIVER TOXICITY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; RECEPTOR BINDING;

EID: 0031753039     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.2824     Document Type: Article

References (36)

1. Alexander, H. R., G. M. Doherty, C. M. Bruesh, D. J. Venzon, and A. Norton. 1991. A recombinant human receptor antagonist to interleukin-1 improved survival after lethal endotoxemia in mice. J. Exp. Med. 173:1029-1032.
2. Aschauer, H., A. Grob, J. Hildebrandt, E. Schuetze, and P. Stuetz. 1990. Highly purified lipid X is devoid of immunostimulatory activity. J. Biol. Chem. 265:9159-9164.
3. Cannon, J. G., R. G. Tompkins, J. A. Gelfand, H. R. Michie, G. G. Stanford, J. W. van der Meer, S. Endres, G. Lonnemann, J. Corsetti, B. Chernow, D. Wilmore, S. M. Wolff, J. F. Burke, and C. A. Dinarello. 1990. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J. Infect. Dis. 161:79-84.
4. Christ, W. J., O. Asano, A. L. C. Robidoux, M. Perez, Y. Wang, G. R. Dubuc, W. E. Gavin, L D. Hawkins, P. D. McGuinness, M. A. Mullarkey, M. D. Lewis, Y. Kishi, T. Kawata, J. R. Bristol, J. R. Rose, D. P. Rossignol, S. Kobayashi, I. Hishinuma, A. Kimura, N. Asakawa, K. Katayama, and I. Yamatsu. 1994. E5531, a pure endotoxin antagonist of high potency: chemistry and biology. Science 268:80-83.
5. Daner, R. L., P. Q. Eichacker, M. E. Doerfler, W. D. Hoffman, J. M. Reilly, J. Willson, T. J. MacVittie, P. P. Stuetz, J. E. Pirrillo, and C. Natanson. 1993. Therapeutic trial of lipid X in a canine model of septic shock. J. Infect. Dis. 167:378-384.
6. Delude, R. L., R. Savedra, Jr., S. Yamamoto, and D. Golenbock. 1995. Use of CD14 transfected cells to study LPS-antagonist action, p. 487-497. In Bacterial endotoxins: lipopolysaccharides from genes to therapy. Wiley-Liss, Inc., New York, N.Y.
7. Galanos, C., M. A. Freudenberg, and W. Reutter. 1979. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. USA 76:5939-5943.
8. Galanos, C., E. T. Rietschel, O. Luderitz, O. Westphal, Y. B. Kim, and D. W. Watson. 1972. Biological activities of lipid A complexed with bovine serum albumin. Eur. J. Biochem. 31:230.
9. Golenbock, D. T., R. Y. Hampton, N. Qureshi, K. Takayama, and C. R. H. Raetz. 1991. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J. Biol. Chem. 266:19490-19498.
10. Hishinuma, I., J. Nagakawa, K. Hirota, K. Miyamoto, T. Yamanaka, K. Tsukidate, K. Katayama, and I. Yamatsu. 1990. Involvement of tumor necrosis factor-α in development of hepatic injury in galactosamine-sensitized mice. Hepatology 12:1187-1191.
11. Karmen, A., F. Wróblewski, and J. S. LaDue. 1955. Transaminase activity in human blood. J. Clin. Invest. 34:126-133.
12. Kawata, T., J. R. Bristol, J. R. Rose, D. P. Rossignol, W. J. Christ, O. Asano, G. R. Dubuc, W. E. Gavin, L. D. Hawkins, Y. Kishi, P. D. McGuiness, M. A. Mullarkey, M. Perez, A. L. C. Robidoux, Y. Wang, S. Kobayashi, A. Kimura, K. Katayama, and I. Yamatsu. 1995. Anti-endotoxin activity of a novel synthetic lipid A analog, p. 499-509. In Bacterial endotoxins: lipopolysaccharides from genes to therapy. Wiley-Liss, Inc., New York, N.Y.
13. Kobayashi, Y., M. Asada, M. Higuchi, and T. Osawa. 1982. Human T cell hybridomas producing lymphokines. 1. Establishment and characterization of human T cell hybridomas producing lymphotoxin and migration inhibitory factor. J. Immunol. 128:2714-2718.
14. Kovach, N. L., E. Yee, R. S. Munford, C. R. H. Raetz, and J. M. Harlan. 1990. Lipid IVa inhibits synthesis and release of tumor necrosis factor induced by lipopolysaccharide in human whole blood ex vivo. J. Exp. Med. 172:77-84.
15. Lam, C., J. Hildebrandt, E. Schutze, B. Rosenwirth, R. A. Proctor, E. Liehl, and P. Stutz. 1991. Immunostimulatory but not antiendotoxin activity of lipid X is due to small amounts of contaminating N, O-acylated disaccharide-1-phosphate. Infect. Immun. 59:2351-2358.
16. Lei, M.-G., N. Qureshi, D. C. Morisson. 1993. Lipopolysaccharide (LPS) binding to 73-kDa and 38-kDa surface proteins on lymphoreticular cells. Immunology Lett. 36:245-250.
17. Loppnow, H., P. Libby, M. Freudenberg, J. H. Krauss, J. Weckesser, and H. Mayer. 1990. Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect. Immun. 58:3743-3750.
18. Lynn, W. A., and D. T. Golenbock. 1992. Lipopolysaccharide antagonists. Immunol. Today 13:271-276.
19. Morrison, D. C., M.-G. Lei, T. Kirikae, and T.-Y. Chen. 1993. Endotoxin receptors on mammalian cells. Immunobiology 187:212-226.
20. Nagakawa, J., I. Hishinuma, K. Hirota, K. Miyamoto, T. Yamanaka, K. Tsukidate, K. Katayama, and I. Yamatsu. 1990. Involvement of tumor necrosis factor-α in the pathogenesis of activated macrophage-mediated hepatitis. Gastroenterology 99:758-765.
21. Proctor, R. A., J. A. Will, K. E. Burhop, and C. R. H. Reatz. 1986. Protection of mice against lethal endotoxemia by a lipid A precursor. Infect. Immun. 52: 905-907.
22. Qureshi, N., K. Takayama, and R. Kurtz. 1991. Diphosphoryl lipid A obtained from the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides is an endotoxin antagonist in mice. Infect. Immun. 59:441-444.
23. Raetz, C. R. H., R. J. Ulevitch, S. D. Wright, C. H. Sibley, A. Ding, and C. F. Nathen. 1993. Gram negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J. 5:2652-2660.
24. Rose, J. R., W. J. Christ, J. R. Bristol, T. Kawata, and D. P. Rossignol. 1995. Agonistic and antagonistic activities of bacterially-derived Rhodobacter sphaeroides lipid A: comparison with activities of synthetic material of the proposed structure and analogs. Infect. Immun. 63:833-899.
25. Snedecor, G. W., and W. G. Cochran. 1967. Statistical methods, 6th ed. Iowa State University Press, Ames.
26. Sufferdini, A. F., R. E. Fromm, M. M. Parker, M. Brenner, J. A. Kovacs, R. A. Wesley, and J. E. Parrillo. 1989. The cardiovascular response of normal humans to the administration of endotoxin. N. Engl. J. Exp. Med. 321:280-287.
27. Suter E., G. E. Ullman, and R. G. Hoffman. 1958. Sensitivity of endotoxin after vaccination with BCG (bacillus Calmette-Guerin). Proc. Soc. Exp. Biol. Med. 99:167-169.
28. Takayama, K., N. Qureshi, B. Beutler, and T. Kirkland. 1989. Diphosphoryl lipid A from Rhodopseudomonas sphaeroides ATCC 17023 blocks induction of cachectin in macrophages by lipopolysaccharide. Infect. Immun. 57:1336-1338.
29. Tracey, K. J., Y. Fong, D. G. Hesse, K. R. Manogue, A. T. Lee, C. Kuo, S. F. Lowry, and A. Cerami. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature (London) 330:662-664.
30. Vogel, S. N., R. N. Moore, J. D. Sipe, and D. L. Rosenstreich. 1980. BCG-induced enhancement of endotoxin sensitivity in C3H/HeJ mice. J. Immunol. 124:2004-2009.
31. Voller, A., D. E. Bidwell, and A. Bartlett. 1977. The enzyme linked immunosorbent assay (ELISA), p. 3-37. Flowline Publications.
32. Westphal, O. 1975. Bacterial endotoxins. Int. Arch. Allergy Appl. Immunol. 49:1-43.
33. Wollenweber, H.-W., and D. C. Morrison. 1985. Synthesis and biological characterization of a photoactivatable, iodinatable, cleavable bacterial lipopolysaccharide derivative. J. Biol. Chem. 260:15068-15074.
34. Yamazaki, S., E. Onishi, K. Enami, K. Natori, M. Kohase, H. Sakamoto, M. Tanouchi, and H. Hayashi. 1986. Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor. Jpn. J. Med. Sci. Biol. 39:105-118.
35. Ziegler, E. J., J. A. Maccutchan, J. Fierer, M. P. Glauser, J. Sadoff, H. Douglas, and A. I. Braude. 1982. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307:1225-1230.
36. Ziegler, E. J., C. J. Fisher, Jr., C. L. Sprung, R. C. Straube, J. C. Sadoff, G. E. Foulke, C. H. Wortel, M. P. Fink, R. P. Dellinger, N. N. H. Teng, I. E. Allen, H. J. Berger, G. L. Knatterud, A. F. LoBuglio, C. R. Smith, and The HA-1A Sepsis Study Group. 1991. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N. Engl. J. Med. 324:429-436.